AstraZeneca Results Presentation Deck
BioPharmaceuticals: Cardiovascular, Renal and Metabolism
Total Revenue $6.0bn; growth +10%
Farxiga: 51% growth to $2.1bn
Strong momentum continues, fastest growing SGLT2i globally
22
$m
900
800
700
600
500
400
300
200
100
0
Q4
2019
Q1 Q2
Q3
2020
US Europe EROW EM
Q4
Q1.
Q2
2021
Q3
• US +31%, Europe +50% and EMS +74%,
boosted by HF and CKD launches
• CKD approval in Europe and Japan
obtained in the quarter
Updated ESC guidelines now
recommend Farxiga as 1st-line
treatment for HFrEF
Forxiga
#1 innovative
anti-diabetic
in China and
Brazil
US branded K+ binder TRX share¹
Branded leadership extended in the US
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Jul 2019
Sep 2019
Lokelma
Nov 2019
SGLT2i = Sodium-glucose transport protein 2 inhibitor; HFrEF = Heart failure with reduced ejection fraction; K+ = potassium; TRx = total prescriptions. 1. IQVIA US monthly total prescription share data
Jan 2020
Mar 2020
May 2020
Lokelma Branded competitor
Jul 2020
Sep 2020
Nov 2020
Jan 2021
Mar 2021
May 2021
Jul 2021
Volume growth US and Japan, Europe
benefitting from new launches
Sep 2021
ESC guidelines now recommend novel
K+ binders to manage hyperkalaemia
58%
BView entire presentation